Clinical Trials Browser

Phase 2 × INDUSTRY × avelumab × Clear all

NCT06225596 2026-05-27

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT05327530 2026-04-24

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05419362 2025-12-16

GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT06557278 2025-10-21

COMUNITY

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04215146 2025-01-16

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Phase 2 Active not recruiting

48 enrolled 13 charts

Breast Neoplasms

NCT06424717 2024-09-27

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03853317 2024-08-09

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

Phase 2 Terminated

9 enrolled 13 charts

Carcinoma, Merkel Cell

NCT04393753 2024-05-08

MERKLIN2

Phase 2 Completed

Carcinoma, Merkel Cell

NCT03472560 2024-04-09

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Phase 2 Terminated

61 enrolled 26 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT02155647 2024-03-13

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

Phase 2 Completed

204 enrolled 32 charts

Carcinoma, Merkel Cell

NCT03565991 2023-09-25

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Phase 2 Terminated

202 enrolled 31 charts

Hereditary Sensory and Autonomic Neuropathies

NCT05107427 2023-04-18

AVENU

Phase 2 Withdrawn

Carcinoma, Transitional Cell

NCT03717155 2022-06-06

Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

Phase 2 Completed

43 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT04874831 2021-11-18

Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

Phase 2 Withdrawn

Carcinoma, Merkel Cell

NCT03258398 2019-07-18

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms